



03-22-04

Express Mail No.: EV 335 859 291 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Bhagwat et al.

Confirmation No. 9314

U.S. Application No. 10/718,185

Group Art Unit: 1626

Filed: November 19, 2003

Examiner: To be assigned

For: INDAZOLE COMPOUNDS,
COMPOSITIONS THEREOF AND
METHODS OF TREATMENT
THEREWITH

Attorney Docket No.: 10624-143-999

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56 and 1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or might be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to references **AA-CO**, which are listed on the accompanying revised Form PTO-1449 entitled "List of References Cited By Applicant."

The above-identified application is a continuation-in-part of U.S. Patent Application No. 10/414,839, filed April 16, 2003, which is a continuation-in-part of U.S. Patent Application No. 09/910,950, filed July 23, 2001. References **AA-CO** are of record in U.S. Patent Application No. 09/910,950. Therefore, pursuant to 37 C.F.R. §1.98(d), copies of these references are not submitted herewith.

Identification of the listed references is not to be construed as an admission that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review references **AA-CO** identified on the attached Form PTO-1449 and make them of record in the file history of the above-identified application by initializing the attached Form PTO-1449.

Pursuant to 37 C.F.R. § 1.97(b)(3), since this Information Disclosure Statement is being submitted before the mailing of a first Office action on the merits, no fee is believed to be due. However, should the Patent and Trademark Office determine that a fee is required, please charge the required fee to Jones Day Deposit Account No. 50-3013. A duplicate of this document is enclosed for accounting purposes.

Respectfully submitted,

Anthony M. Insogna, Reg. No. 35,203

By: *Michael D. Spina, Reg. No. 47,458* 35,203

Date March 18, 2004

Anthony M. Insogna

(Reg. No.)

JONES DAY

222 East 41st Street

New York, New York 10017

(212) 326-3939



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

10624-143-999

APPLICATION NO

10/718,185

APPLICANT

Bhagwat et al.

FILING DATE

November 19, 2003

GROUP

1626

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	3,541,110	11/17/70	Bell et al.			
	AB	3,994,890	11/30/76	Fujimura			
	AC	4,415,569	11/15/83	Yasuo et al.			
	AD	5,985,867	11/16/99	Rodgers et al.			
	AE	6,162,613	12/19/00	Su et al.			
	AF	6,531,491	3/11/03	Kania et al.			
	AG	6,534,524	3/18/03	Kania et al.			
	AH	6,555,539	4/29/03	Reich			
	AI	U.S. pub. no. 2002/0161022	10/31/02	Reich			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AJ	WO 99/53927	10/29/99	PCT				
	AK	WO 02/085396	10/31/02	PCT				
	AL	WO 02/10137	2/7/02	PCT				
	AM	WO 01/12621 A1	2/22/01	PCT				
	AN	WO 98/43969	10/8/98	PCT				
	AO	WO 89/10924	11/16/89	PCT				
	AP	GB 1293557	09/04/70	Great Britain				
	AQ	GB 1 489 280	10/19/77	Great Britain				
	AR	GB 2 345 486A	7/12/00	Great Britain				
	AS	EP 0 494 774	7/15/92	Europe				
	AT	EP 0 518 805	12/16/92	Europe				
	AU	DE 12 66 763 B	4/25/68	Germany				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AV	Spiegelman et al., 1993 "Regulation of Adipocyte Gene Expression in Differentiation and Syndromes of Obesity/Diabetes", <i>J. of Biol. Chem.</i> 268:6823-6826.
	AW	Hirosumi et al., 2002 "A central role for JNK in obesity and insulin resistance", <i>Letters to Nature</i> 420:333-336.
	AX	Andronati, 1994, "Synthesis of 1-[4-(4-phenyl-1-piperazinyl)butyl]-1,2-dihydro-3H-1,4-benzodiazepin-2-ones and -1H-indazoles and their affinity for benzodiazepine receptors" <i>Dopov. Akad. Nauk. Ukr.</i> 8:126-131.
	AY	Arya, 1977, "Synthesis of nitroheterocycles: Part IV" <i>Indian J. Chem., Sect. B</i> , 15B(7):625-628.

AZ	Aspenström et al., 1996, "Two GTPases, Cdc42 and Rac, bind directly to a protein implicated in the immunodeficiency disorder Wiskott-Aldrich syndrome", <i>Curr. Biol.</i> 6 :70-75
BA	Boehm, 2000, "Novel Inhibitors of DNA Gyrase"" <i>J. Med. Chem.</i> 43 (14):2664-2674.
BB	Buck, 1993, "Total synthesis of peruvianine" <i>Heterocycles</i> 36 (11):2489-2495.
BC	Chen et al., 1996, "Activation and inhibition of the AP-1 complex in human breast cancer cells", <i>Mol. Carcinogenesis</i> 15 :215-226
BD	Dong et al., 1998, "Defective T cell differentiation in the absence of <i>Jnk1</i> ", <i>Science</i> 282 :2092-2095
BE	Faris et al., 1996, "Regulation of interleukin-2 transcription by inducible stable expression of dominant negative and dominant active mitogen-activated protein kinase kinase kinase in Jurkat T cells", <i>J. Biol. Chem.</i> 271 :27366-27373
BF	Fujimura, 1986, "Synthesis and pharmacological activities of 2,3-dihydro-1H-pyrazolo[1,2a]indazolium derivatives" <i>Yakugaku Zasshi</i> 106 (11):1002-1007
BG	Gum et al., 1997, "Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase- dependent signaling cascades", <i>Oncogene</i> 14 :1481-1493
BH	Han et al., 1999, "Jun N-terminal kinase in rheumatoid arthritis", <i>J. Pharmacol. Exp. Therap.</i> 291 :124-130
BI	Hibi et al., 1993, "Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain", <i>Genes Dev.</i> 7 :2135-2148
BJ	Ishizuka et al., 1997, "Mast cell tumor necrosis factor α production is regulated by MEK kinases", <i>Proc. Natl. Acad. Sci. USA</i> 94 :6358-6363
BK	Jones, 1983, "The reaction of 4-alkyl-3-thiosemicarbazides with beta-halo ketones" <i>J. Heterocycl. Chem.</i> 20 (5):1359-1361
BL	Karin et al., 1997, "AP-1 function and regulation", <i>Curr. Opin. Cell. Biol.</i> U9 :240-246
BM	Kawakami, 2000, "NaH-Mediated One-Pot cyclocondensation of 6-nitroquinoline with aromatic hydrazones to form (1,2,4)triazino(6,5f)quinoline and/or pyrazolo(3,4f)quinoline" <i>Organic Letters</i> 2 (3): 413-415 .
BN	Lange-Carter et al., 1993, "A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf", <i>Science</i> 260 :315-319
BO	Li et al., 1996, "Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4 ⁺ T cells", <i>Science</i> 271 :1272-1276
BP	Li et al., 1996, "The Ras-JNK pathway is involved in shear-induced gene expression", <i>Mol. Cell. Biol.</i> 16 :5947-5954
BQ	Lin et al., 1995, "Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2", <i>Science</i> 268 :286-290
BR	Manning and Mercurio, 1997, "Transcription inhibitors in inflammation", <i>Exp. Opin. Invest. Drugs</i> 6 :555-567
BS	Milne et al., 1995, "p53 is phosphorylated <i>in vitro</i> and <i>in vivo</i> by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1", <i>J. Biol. Chem.</i> 270 :5511-5518
BT	Mohit et al., 1995, "p49 ^{3F12} kinase: a novel MAP kinase expressed in a subset of neurons in the human nervous system", <i>Neuron</i> 14 :67-78
BU	Nishina et al., 1997, "Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4 (MKK4)-deficient T lymphocytes", <i>J. Exp. Med.</i> 186 :941-953
BV	Okamoto et al., 1997, "Selective activation of the JNK/AP-1 pathway in Fas-mediated apoptosis of rheumatoid arthritis synoviocytes", <i>Arthritis & Rheumatism</i> 40 :919-926
BW	Patel, 1999, "Unsymmetrical Cyclic Ureas as HIV-1 Protease Inhibitors", <i>Bioorganic and Medicinal Chemistry Letters</i> 9 (22):3217-3220.
BX	Pfoertner, 1982, "Preparation of 1H indazoles by photolysis", <i>Helv. Chim. Acta</i> 65 (3):798-806.
BY	Pombo et al., 1994, "The stress-activated protein kinases are major c-Jun amino-terminal kinases activated by ischemia and reperfusion", <i>J. Biol. Chem.</i> 269 :26546-26551
BZ	Raitano et al., 1995, "The <i>Bcr-Abl</i> leukemia oncogene activates Jun kinase and requires Jun for transformation", <i>Proc. Natl. Acad. Sci. USA</i> 92 :11746-11750
CA	Sabapathy et al., 1999, "JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development", <i>Curr. Biol.</i> 9 :116-125
CB	Su et al., 1994, "JNK is involved in signal integration during costimulation of T lymphocytes", <i>Cell</i> 77 :727-736

	CC	Swantek et al., 1997, "Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF- α) translation: glucocorticoids inhibit TNF- α translation by blocking JNK/SAPK", Mol. Cell. Biol. <u>17</u> :6274-6282
	CD	Szabo et al., 1996, "Altered cJUN expression: an early event in human lung carcinogenesis", Cancer Res. <u>56</u> :305-315
	CE	Tournier et al., 1997, "Mitogen-activated protein kinase kinase 7 is an activator of the c-Jun NH ₂ -terminal kinase", Proc. Natl. Acad. Sci. USA <u>94</u> :7337-7342
	CF	Vasilevsky, 1996, "Cyclocondensation of activated acetylenes with hydrazine: A novel route to substituted indazoles" Mendeleev. Commun. <u>3</u> :98-99.
	CG	Whitmarsh and Davis, 1996, "Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways", Mol. Med. <u>74</u> :589-607
	CH	Wrzeciono, 1985, "Azoles: Part 14" Pharmazie <u>40</u> (2):105-108
	CI	Wrzeciono, 1992, "Azoles: Part 33" Pharmazie <u>47</u> (1):22-24
	CJ	Yan et al., 1994, "Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1", Nature <u>372</u> :798-800
	CK	Yang et al., 1998, "Differentiation of CD4 ⁺ T cells to Th1 cells requires MAP kinase JNK2", Immunity <u>9</u> :575-585
	CL	Yin et al., 1997, "Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney", J. Biol. Chem. <u>272</u> :19943-19950
	CM	Rickenger et al., CA <u>116</u> :235509 (1992)
	CN	Grayshan et al., CA <u>112</u> :216936 (1990)
	CO	Walser et al., CA <u>83</u> :164108 (1975)

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	